Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenoxodiol combined with platinum or taxane chemotherapy for recurrent platinum- and/or taxane-resistant ovarian, fallopian tube, or primary peritoneal cancer
ACTRN12605000432617Phase 2Completed
- Sponsor
- MEI Pharma
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idronoxil in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by MEI Pharma. Started Apr 2004; status: completed.
02
Drugs
idronoxil
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12605000432617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000432617.